Page last updated: 2024-09-03

gefitinib and vorinostat

gefitinib has been researched along with vorinostat in 22 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(vorinostat)
Trials
(vorinostat)
Recent Studies (post-2010) (vorinostat)
5,2315662,9192,5291811,840

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)vorinostat (IC50)
Chain A, Histone deacetylase-like amidohydrolaseAlcaligenaceae bacterium FB1880.95
Chain A, Histone deacetylase-like amidohydrolaseAlcaligenaceae bacterium FB1880.95
Histone deacetylase 8Schistosoma mansoni1.3147
Histone deacetylase Rattus norvegicus (Norway rat)0.165
Gli1Mus musculus (house mouse)2.23
nuclear receptor subfamily 0 group B member 1Homo sapiens (human)0.7472
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)1.55
Histone deacetylase 1Mus musculus (house mouse)0.1121
Histone deacetylase 3Homo sapiens (human)0.3382
Bromodomain-containing protein 4Homo sapiens (human)0.2644
Nuclear receptor corepressor 1Homo sapiens (human)0.0382
Epidermal growth factor receptorHomo sapiens (human)0.456
Tubulin alpha-1A chainSus scrofa (pig)1.5
Tubulin beta chainSus scrofa (pig)1.5
AlbuminHomo sapiens (human)0.1072
Leukotriene A-4 hydrolaseHomo sapiens (human)4.66
Cytochrome P450 2C8Homo sapiens (human)0.0903
Cytochrome P450 2D6Homo sapiens (human)0.011
Cytochrome P450 2C9 Homo sapiens (human)0.24
Androgen receptorRattus norvegicus (Norway rat)0.1582
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)2.8
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.053
Cannabinoid receptor 1Rattus norvegicus (Norway rat)0.116
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)2.8
Leukotriene A-4 hydrolaseMus musculus (house mouse)6.15
Cytochrome P450 2C19Homo sapiens (human)0.042
Prostaglandin G/H synthase 2Homo sapiens (human)0.13
Delta-type opioid receptorHomo sapiens (human)7.2
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)2.8
Histamine H2 receptorCavia porcellus (domestic guinea pig)7.2
Histone deacetylase 4Homo sapiens (human)0.6096
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.086
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.322
Platelet-activating factor acetylhydrolaseHomo sapiens (human)0.1
Histone deacetylase 1Homo sapiens (human)0.2701
Histone deacetylase 1Rattus norvegicus (Norway rat)0.165
Histone deacetylase Rattus norvegicus (Norway rat)0.165
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)0.07
ReninMacaca fascicularis (crab-eating macaque)0.067
Histone deacetylase 3Rattus norvegicus (Norway rat)0.165
Histone deacetylase-like amidohydrolaseAlcaligenaceae bacterium FB1881
Histone deacetylase Plasmodium falciparum 3D70.1
Histone deacetylase 7Homo sapiens (human)0.6115
Histone deacetylase 2Homo sapiens (human)0.3746
HD2 type histone deacetylase HDA106 Zea mays0.2227
Polyamine deacetylase HDAC10Homo sapiens (human)0.4211
Histone deacetylase 11 Homo sapiens (human)0.5235
Carboxypeptidase B2Homo sapiens (human)0.362
Histone deacetylase 7Rattus norvegicus (Norway rat)0.165
Histone deacetylase 6 Rattus norvegicus (Norway rat)0.165
Histone deacetylase 4Rattus norvegicus (Norway rat)0.165
Histone deacetylase 8Homo sapiens (human)0.9141
Histone deacetylase 6Homo sapiens (human)0.2634
Histone deacetylase 9Homo sapiens (human)0.5614
Histone deacetylase 5Homo sapiens (human)0.5926
Histone deacetylase Plasmodium falciparum (malaria parasite P. falciparum)0.0945
Nuclear receptor corepressor 2Homo sapiens (human)0.0905
Histone deacetylase 6Mus musculus (house mouse)0.3742
Histone deacetylase Zea mays0.029

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.55)29.6817
2010's18 (81.82)24.3611
2020's3 (13.64)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Li, Y; Lu, SM; Zhang, SQ; Zheng, YW; Zuo, M1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, S; Chen, YZ; Ding, C; Hu, G; Jiang, Y; Li, L; Tan, C; Zhang, C; Zhang, W1
Chu, B; Ding, C; Fan, T; Jiang, Y; Shi, Z; Sun, Q; Tan, C; Yuan, Z; Zhang, C; Zhao, L1
Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Khochbin, S; Niang, C; Sancey, L1
Beck, JF; Kurtze, I; Sonnemann, J1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M1
Armini, A; Bianchi, L; Bini, L; Bruzzese, F; Budillon, A; Di Gennaro, E; Gagliardi, A; Gimigliano, A; Leone, A; Pucci, B; Puglia, M; Rocco, M1
Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S1
Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T1
Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Roca, MS; Terranova-Barberio, M; Vitagliano, C1
Ando, M; Fujiwara, T; Hasegawa, Y; Inoue, A; Katakami, N; Nagase, K; Shimizu, S; Takahashi, T; Takeuchi, S; Yano, S; Yoshimura, K1
Coll, JL; Couvet, M; Didier, C; Gauche, C; Henry, M; Hurbin, A; Jeannot, V; Josserand, V; Lecommandoux, S; Mazzaferro, S; Schatz, C; Vanwonterghem, L; Vollaire, J1
Choi, EK; Hwang, JJ; Jeong, SY; Kim, CS; Kim, DE; Kim, MJ; Lee, JS; Park, SE; Rho, JK1
Bellini, A; Carey, TE; Chiocca, S; Citro, S; Ghiani, L; Miccolo, C1
Ando, M; Arai, S; Fujiwara, T; Fukuda, K; Hase, T; Hasegawa, Y; Hata, A; Katakami, N; Kawakami, T; Ko, TK; Murakami, H; Nagase, K; Nishiyama, A; Ong, ST; Shimizu, S; Takahashi, T; Takeuchi, S; Tanimoto, A; Yano, S; Yoshimura, K1
Chen, J; Chen, X; Huang, L; Li, X; Lin, Q; Wong, KC; Xie, W; Zheng, Z1

Reviews

2 review(s) available for gefitinib and vorinostat

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012

Trials

3 trial(s) available for gefitinib and vorinostat

ArticleYear
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat

2015
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
    The journal of medical investigation : JMI, 2017, Volume: 64, Issue:3.4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; Quinazolines; Vorinostat

2017
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.
    Cancer science, 2020, Volume: 111, Issue:2

    Topics: Aged; Aged, 80 and over; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Sequence Deletion; Survival Analysis; Treatment Outcome; Vorinostat

2020

Other Studies

17 other study(ies) available for gefitinib and vorinostat

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.
    Bioorganic & medicinal chemistry, 2012, Jul-15, Volume: 20, Issue:14

    Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Histone Deacetylase Inhibitors; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; Protein Kinase Inhibitors; Salicylamides; Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
    Bioorganic & medicinal chemistry, 2017, 01-01, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles

2017
Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship

2021
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:3

    Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Histone Acetyltransferases; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Ku Autoantigen; Lung Neoplasms; Mice; Quinazolines; Subcellular Fractions; Vorinostat

2010
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
    Oncology reports, 2011, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat

2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Journal of cellular physiology, 2011, Volume: 226, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat

2011
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.
    Proteomics, 2011, Volume: 11, Issue:18

    Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Mass Spectrometry; Peptide Mapping; Protein Isoforms; Proteomics; Quinazolines; Software; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Two-Dimensional Difference Gel Electrophoresis; Vorinostat

2011
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Cancer research, 2013, Apr-15, Volume: 73, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Membrane Proteins; Mice; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays

2013
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Free radical biology & medicine, 2015, Volume: 89

    Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Voltage-Dependent Anion Channel 1; Vorinostat

2015
Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer.
    Journal of controlled release : official journal of the Controlled Release Society, 2018, 04-10, Volume: 275

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Female; Gefitinib; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lung Neoplasms; Mice, Nude; Nanoparticles; Vorinostat

2018
Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
    Oncology reports, 2019, Volume: 41, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Reactive Oxygen Species; Vorinostat

2019
Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.
    British journal of cancer, 2019, Volume: 120, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Gefitinib; Histone Deacetylase Inhibitors; Humans; Papillomaviridae; Papillomavirus Infections; Protein Kinase Inhibitors; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; Transcription Factors; Tumor Suppressor Proteins; Vorinostat

2019
Enabling Single-Cell Drug Response Annotations from Bulk RNA-Seq Using SCAD.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023, Volume: 10, Issue:11

    Topics: Gefitinib; RNA-Seq; Sequence Analysis, RNA; Transcriptome; Vorinostat

2023